## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-chemo`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-chemo/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-chemo/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-chemo/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-chemo/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-chemo/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-chemo/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-chemo` v2 · content_hash `a40e1b79fd2b41d3…` · thread_head genesis · 20 DIVs
- **thesis (c1):** SS-31 binds cardiolipin and improves mitochondrial bioenergetics in preclinical models.
  - c3 [human/active] Gabapentinoids show no significant benefit for preventing chemo-induced peripheral neuropathy in meta-analyses.
  - c4 [human/active] SS-31 has completed Phase 2/3 trials in primary mitochondrial myopathy and received FDA approval for Barth syndrome.
  - c2 [preclinical/active] In C26 tumor-bearing mice, SS-31 preserved mitochondrial function in cardiac and diaphragm muscle during chemotherapy.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-chemo/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-chemo/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-chemo`
- **title:** SS-31 (Elamipretide) for Chemotherapy Side Effects: Mitochondrial Evidence Review
- **url:** https://miscsubjects.com/a/ss-31-chemo
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:01.799Z
- **tags:** peptide, matrix

## Body

## What's breaking down

Chemotherapy often damages mitochondria in healthy tissues. This leads to reduced ATP production, higher reactive oxygen species, and impaired energy metabolism in muscle, nerve, and other cells. The result can include fatigue, muscle weakness, and peripheral neuropathy. These changes tip the balance toward degeneration because repair pathways cannot keep up with ongoing oxidative stress and energy deficits. Gabapentin and pregabalin are sometimes used alongside to manage resulting nerve pain, but they act on symptoms rather than the underlying mitochondrial layers.

## Why SS-31 (Elamipretide) might help you

1. Chemotherapy impairs mitochondrial cardiolipin and electron transport chain efficiency in non-cancer tissues.
2. SS-31 binds cardiolipin in the inner mitochondrial membrane.
3. This stabilizes membrane structure and improves electron transfer while lowering ROS leak.
4. Therefore for you: If mitochondrial dysfunction from chemo is part of your fatigue or weakness profile, SS-31 is discussed because it targets tissue repair pathways at the organelle level rather than masking downstream signals.

## Why Gabapentin / pregabalin matters for you

1. These drugs bind the alpha2-delta subunit of voltage-gated calcium channels.
2. This reduces presynaptic calcium influx and lowers release of excitatory neurotransmitters involved in pain signaling.
3. Therefore for you: Gabapentin/pregabalin suppresses neuropathic pain signals; it does not repair nerve mitochondria or reverse chemo-induced degeneration. Any relief comes from lowered symptom load, which may improve daily function but trades off against direct support for mitochondrial repair.

## How these fit together

SS-31 addresses the mitochondrial layer of chemo damage through cardiolipin stabilization and bioenergetic support. Gabapentin/pregabalin operates at the symptom-suppression layer by modulating calcium-dependent pain transmission. In a single-compound focus on SS-31, the two do not overlap mechanistically; one targets root energy deficits while the other manages downstream excitability. If both layers are active, mitochondrial repair via SS-31 could theoretically reduce the need for prolonged signal suppression, though no combined data exist.

## What the evidence actually shows

A 2020 mouse study using the C26 tumor model plus chemotherapy found daily SS-31 preserved mitochondrial function in heart and diaphragm muscle and prevented muscle weakness (preclinical tier). A 2021 study in tumor-bearing mice showed SS-31 rescued metabolic impairments from both tumor burden and chemotherapy in skeletal muscle and liver (preclinical tier). Human trials of SS-31 exist for primary mitochondrial myopathy and Barth syndrome but none specifically for chemotherapy side effects (human tier limited to other indications). Gabapentinoid meta-analyses for chemo-induced neuropathy show no significant prevention benefit and inconsistent treatment effects (human tier).

## What scientists say

Researchers note SS-31 improves mitochondrial coupling and reduces oxidative stress in multiple preclinical stress models, including chemotherapy myotoxicity. Clinical development has focused on genetic mitochondrial disorders where cardiolipin defects are central. Experts emphasize that benefits seen in rare-disease trials do not automatically translate to acquired mitochondrial stress from chemotherapy.

## What people say on Reddit

Discussions on peptide and cancer forums mention interest in SS-31 for post-chemo fatigue based on mitochondrial mechanisms, but reports remain anecdotal with no verified user outcomes tied to chemotherapy (anecdotal tier, sparse).

## What people say on X

Posts referencing SS-31 or elamipretide in cancer contexts are rare and primarily share preclinical papers rather than personal experience (anecdotal tier, minimal).

## What we do not know

No human trials test SS-31 specifically during or after chemotherapy. Long-term effects on cancer recurrence risk or interactions with ongoing chemo regimens remain unstudied. Evidence grading shows heavy reliance on rodent models of chemo myotoxicity.

## Safety and limits

SS-31 has completed multiple human trials in mitochondrial disease populations with injection-site reactions as the main noted effect. It received accelerated FDA approval for Barth syndrome in 2025 based on functional improvements in small cohorts. No safety data exist for the chemotherapy setting. All claims here are graded by evidence tier and separate human data from preclinical and anecdotal sources.

## Claims (4)

- **c1** [mechanistic w=0.3] SS-31 binds cardiolipin and improves mitochondrial bioenergetics in preclinical models.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c3** [human w=0.8] Gabapentinoids show no significant benefit for preventing chemo-induced peripheral neuropathy in meta-analyses.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c4** [human w=0.8] SS-31 has completed Phase 2/3 trials in primary mitochondrial myopathy and received FDA approval for Barth syndrome.
  - who_claims: grok/grok-4.3
  - sources: s4
- **c2** [preclinical w=0.5] In C26 tumor-bearing mice, SS-31 preserved mitochondrial function in cardiac and diaphragm muscle during chemotherapy.
  - who_claims: grok/grok-4.3
  - sources: s2

## Voxel graph (4 atoms · 8 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-chemo/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `be4c2d147f8e3765`

### s1 · review · ok
- title: SS-31 (Elamipretide) — Peptide Evidence Score
- url: https://biomeme.com/applications/wellness/peptide-evidence/ss-31/
- summary: Mechanism summary for cardiolipin binding and bioenergetics.
- quote: SS-31 selectively targets and stabilizes cardiolipin in the inner mitochondrial membrane.
- claim_ids: c1
- hash: `981eca55da2f81f9`

### s2 · pubmed · ok
- title: Pharmacological targeting of mitochondrial function and ROS production...
- url: https://pubmed.ncbi.nlm.nih.gov/31747905/
- summary: Preclinical chemo model results.
- quote: SS-31 treatment preserved mitochondrial function in both cardiac and diaphragm muscle from C26 mice
- claim_ids: c2
- hash: `86863e84e0b1ecd5`

### s3 · pubmed · ok
- title: Gabapentinoids for chemotherapy-induced peripheral neuropathy
- url: https://pubmed.ncbi.nlm.nih.gov/38936970/
- summary: Meta-analysis on gabapentinoids in CIPN.
- quote: pregabalin did not significantly improve average pain... limited evidence to support the use of gabapentinoids in CIPN
- claim_ids: c3
- hash: `ee2e0f1c2dc41bec`

### s4 · news · ok
- title: FDA approves drug for treatment of rare mitochondrial disorder
- url: https://hub.jhu.edu/2025/09/25/fda-approves-barth-syndrome-treatment/
- summary: Human trial and approval data for elamipretide.
- quote: FDA grants accelerated approval first treatment Barth syndrome
- claim_ids: c4
- hash: `be4c2d147f8e3765`

## Provenance (2 model passes)
- chain valid: yes · head: `3119fed792c53294`

- write · grok/grok-4.3 · 2026-06-29T23:57 · hash `06c2148b71f9`
- voxel_divide · owner · 2026-07-17T02:42 · hash `3119fed792c5`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-chemo/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-chemo/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-chemo","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-chemo|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-chemo|tier|assertion`
- **iMessage ask:** `ss-31-chemo|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-chemo`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-chemo/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-chemo/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*